Inhibitors of C5 complement enhance vaccinia virus oncolysis

Cancer Gene Therapy

Volumn 20, Issue 6, 2013, Pages 342-350

  Magge, D ^a,b   Guo, Z S ^a,b   O'Malley, M E ^a,b   Francis, L ^a,b   Ravindranathan, R ^a,b   Bartlett, D L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

C5; cobra venom factor; complement; compstatin; SSL7; vaccinia virus

Indexed keywords

COMPLEMENT COMPONENT C5 INHIBITOR; ENHANCED GREEN FLUORESCENT PROTEIN; VACCINIA ANTIBODY;

ARTICLE; COMPLEMENT INHIBITION; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; VACCINIA VIRUS; VIRAL CLEARANCE; VIRUS CULTURE; VIRUS EXPRESSION; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS INHIBITION;

ANTIBODIES, VIRAL; CELL LINE; COMPLEMENT C5; HUMANS; IMMUNOSUPPRESSION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VACCINIA VIRUS;

VACCINIA VIRUS;

EID: 84879421849     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.26     Document Type: Article

References (45)

1. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9: 64-71.
2. Smith GL, Vanderplasschen A. Extracellular enveloped vaccinia virus. Entry, egress, and evasion. Adv Exp Med Biol 1998; 440: 395-414. (Pubitemid 28405916)
3. Zeh HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther 2002; 9: 1001-1012. (Pubitemid 35462562)
4. Breitback CJ, Burk J, Jonker D, Stephenson J, Haas AR, Kirn DH et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477: 99-102.
5. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kirn DH et al. Use of a targeted oncolytic virus, JX-594 in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9: 533-542.
6. McCart JA, Ward JM, Lee J, Hun Y, Alexander R, Libutti S et al. Systemic Cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751-8757. (Pubitemid 34013887)
7. Stanford MM, Bell JC, Vaha-Koskela MJ. Novel oncolytic viruses: riding high on the next wave? Cytokine Growth Factor Rev 2011; 21: 177-183.
8. Bourke MG, Salwa S, Harrington KJ, Kucharczyk MJ, Forde PF, de Kruijf M et al. The emerging role of viruses in the treatment of solid tumours. Cancer Treat Rev 2011; 37: 618-632.
9. Moss B. Regulation of vaccinia virus transcription. Ann Rev Biochem 2005; 59: 661-668.
10. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658-670.
11. Tracey KJ. Reflex control of immunity. Nat Rev Immunol 2009; 9: 418-428.
12. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther 2003; 10: 983-990. (Pubitemid 36722433)
13. Janeway CA, Travers P, Walport M, Capra JD, Shlomchik MJ. Immunobiology: The Immune System in Health and Disease. 5th edn. (Garland Science: New York, NY, USA, 2001 509-511.
14. Pier GB, Lyczak JB, Wetzler LM. Immunology, Infection, and Immunity. ASM Press: Washington, DC, USA, 2004 85-109.
15. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004; 5: 971-974. (Pubitemid 41057712)
16. Carrol MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004; 5: 981-986.
17. Lambris J, Ricklin D, Geisbrecht B. Complement evasion by human pathogens. Nat Rev Microbiol 2008; 6: 132-142.
18. Woodruff T, Nandakumar K, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol 2011; 48: 1631-1642.
19. Moulton EA, Atkinson JP. Buller RML. Surviving mousepox infection requires the complement system. PLOS Pathog 2008; 4: e1000249.
20. Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP. Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol 2009; 183: 3150-3159.
21. Bernet J, Mullick J, Singh A, Sahu A. Viral mimicry of the complement system. J Biosci 2003; 28: 249-264. (Pubitemid 36512801)
22. Lambris J, Ricklin D. Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 2008; 632: 273-292.
23. Jayasekera J, Moseman E, Caroll M. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol 2007; 81: 3487-3494. (Pubitemid 46456657)
24. Laursen N, Gordon N, Hermans S, Lorenz N, Jackson N, Anderson GR. Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus. Proc Natl Acad Sci USA 2010; 107: 3681-3686.
25. Sharma S, Jabeen T, Singh RK, Bredhorst R, Vogel CW, Singh TP. Structural studies on the cobra venom factor: isolation, purification, crystallization and preliminary crystallographic analysis. Acta Crystallogr D Biol Crystallogr 2001; 57: 596-598. (Pubitemid 32296040)
26. Alsenz J, Becherer JD, Nilsson B, Lambris JD. Structural and functional analysis of C3 using monoclonal antibodies. Curr Topics Microbiol Immunol 1989; 153: 235-245.
27. Whitehead AS, Sim RB, Bodmer WF. A monoclonal antibody against human complement component C3: the production of C3 by human cells in vitro. Eur J Immunol 1981; 11: 140-146. (Pubitemid 11143416)
28. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995; 92: 8955-8959.
29. Kirschfink M, Mollnes TE. Modern complement analysis. Clin Vaccine Immunol 2003; 10: 982-989. (Pubitemid 37444262)
30. Thomas TC, Rollins SA, Rothers RP, Giannoni MA, Hartman SL, Elliott EA et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996; 33: 1389-1401. (Pubitemid 27196373)
31. Guo ZS, Parimi V, O'Malley ME, Thirunavukasaru P, Sathaiah M, Bartlett DL. The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host. Gene Ther 2010; 17: 1465-1475.
32. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol 2008; 3: 101-116.
33. Penn I. Chemical immunosuppression and cancer. Cancer 1974; 34: 1474-1480.
34. Newstead CG. Assessment of risk of cancer after renal transplantation. Lancet 1998; 351: 610-611. (Pubitemid 28098439)
35. Lun XQ, Jang JH, Tang N, Deng H, Head R, McCart A. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009; 15: 2777-2788.
36. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008; 1785: 217-231.
37. Power A, Wang J, Falls T, Paterson J, Parato KA, Bell J et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 2007; 15: 123-130. (Pubitemid 46043657)
38. Ikeda K, Wakimoto H, Ichikawa T, Jhung S, Hochberg F, Chiocca E et al. Complement depletion facilitates the infection of multiple brain tumors by an intra-vascular, replication-conditional herpes simplex virus mutant. J Virol 2000; 74: 4765-4775. (Pubitemid 30237904)
39. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Diesboeck TS, Chiocca EA et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881-887. (Pubitemid 29372413)
40. Law M, Hollinshead R, Smith GL. Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. J Gen Virol 2002; 83: 209-222. (Pubitemid 34030825)
41. Bernards R, Destree A, McKensie S, Gordon E, Weinberg RA, Panicali D. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci USA 1987; 84: 6854-6858.
42. Li J, O'Malley ME, Urban J, Sampath P, Guo ZS, Kalinski P et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 2011; 19: 650-657.
43. Kirn DH, Wang Y, Liang W, Contag C, Thorne SH. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res 2008; 68: 2071-2075. (Pubitemid 351521777)
44. Isaacs S, Kotwal G, Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Immunol 1992; 89: 628-632.
45. Purushottam J, Kotwal G. Vaccinia complement control protein: multi-functional protein and a potential wonder drug. J Biosci 2003; 28: 265-271. (Pubitemid 36512802)